What's Happening?
Osteoboost Health has successfully raised $8 million in a financing round led by Ambit Health Ventures, with additional investments from Emmeline Ventures, Disrupt Health Impact Fund, Esplanade Ventures, and
Portfolia. The funds will support the development and distribution of Osteoboost, a wearable device designed to combat osteopenia, a precursor to osteoporosis. The device, which is FDA-cleared, delivers targeted vibration therapy to the lumbar spine and hips, areas most susceptible to fractures. Inspired by NASA-funded research, the device has shown significant efficacy in clinical trials, slowing bone density loss by 85% in the spine and 55% in the hips. This innovation addresses a critical gap in treatment options for the nearly 44 million Americans with low bone density, particularly postmenopausal women who currently have limited non-drug therapies available.
Why It's Important?
The introduction of Osteoboost represents a significant advancement in women's health, particularly for those experiencing menopause-related bone density loss. With osteoporosis affecting millions and the associated societal costs being substantial, this device offers a proactive solution to a largely underserved market. The funding will enable Osteoboost Health to expand its reach and potentially alter the trajectory of bone health management. The device's success in clinical trials underscores its potential to reduce fracture risks and improve quality of life for many women. Furthermore, the investment highlights a growing recognition of the need for innovative healthcare solutions in a sector that has historically received minimal private capital.
What's Next?
Osteoboost Health plans to leverage the new funding to enhance its product offerings and expand its market presence. The company is also developing a comprehensive ecosystem for bone health, including Wellen by Osteoboost, a video training platform that has demonstrated improvements in lower-body strength and fall risk reduction. As the device gains traction, it is likely to attract further interest from healthcare providers and investors, potentially leading to broader adoption and additional funding opportunities. The success of Osteoboost could also inspire further innovation and investment in women's health technologies.
